Navigation Links
Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohn's Disease in the European Union
Date:3/7/2013

in moderately to severely active CD and UC patients, who had failed at least one conventional or anti-TNFα therapy.

"With a targeted mechanism of action, vedolizumab has clinical promise as a potential treatment option for people with moderate to severely active CD and UC," said Paul Rutgeerts, M.D., Ph.D., F.R.C.P., professor of medicine, Catholic University of Leuven, Belgium. "While there is no known cure, there is a need for new CD and UC treatment options, in an effort to provide patients with additional choices for managing their disease, reducing symptoms and achieving remission."

About Crohn's disease and ulcerative colitis

Crohn's disease (CD) and ulcerative colitis (UC) are the two most common forms of inflammatory bowel disease (IBD), which is marked by inflammation in the lining of the GI tract. CD can impact any part of the digestive tract, and common symptoms may include abdominal pain, diarrhea, rectal bleeding, weight loss, and/or fever. UC impacts the large intestine only, which includes the colon and the rectum. The most common symptoms of UC include abdominal discomfort and blood or pus in diarrhea. There is no known cause for CD or UC, although many researchers believe that the interaction of an outside agent, such as a virus or bacteria, with the body's immune system may trigger them. No cure exists for CD or UC; the aim of IBD treatments is to induce and maintain remission, or achieve extended periods of time when patients do not experience symptoms.

About vedolizumab

Vedolizumab was developed for the treatment of CD and UC, as a gut-selective, humanized monoclonal antibody that specifically antagonizes the alpha4beta7 (α4β7) integrin, which is expressed on a subset of circulating white blood cells. These cells have been shown to play a role in mediating the inflammatory process in CD and UC. α4β7 binds with a specific adhesion molecule primarily expressed in the intestinal tract. Ther
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
2. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
3. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
4. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
5. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
8. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
9. Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
10. Bayer Submits New Drug Application for Riociguat for the Treatment of Pulmonary Arterial Hypertension and Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension
11. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 Dynatronics Corporation (NASDAQ: ... has been appointed to the Company,s Board of Directors ... the death in November 2014 of board member Joseph ... Linder to our Board of Directors represents an important ... , chairman and president of Dynatronics.  "Rich is a proven ...
(Date:3/27/2015)... 27, 2015 Biopharmaceutical Industry Leads Manufacturing ... comes out on top as the country,s manufacturing leader ... report  from ndp│analytics. According to the  analysis , the ... over the last decade, accounting for 27 percent of ... A Short Video on Medicare Part D ...
(Date:3/27/2015)... DIEGO , March 27, 2015   ... company, today announced new data showing that, compared ... TM technology provided highly equivalent interpretations of ... disease, and did so in a fraction of ... the way for more comprehensive genetic analysis in ...
Breaking Medicine Technology:Dynatronics Announces Appointment of Richard J. Linder to Board of Directors 2Week in Review: The Latest from PhRMA 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3
... People recovering,from acute heart problems such as ... develop habits to control heart attack risk factors ... to researchers at,Mayo Clinic in Rochester. These managers ... programs that last,three years. With these risk factors ...
... 4 AstraZeneca (NYSE:,AZN) today announced that it ... U.S. Food and Drug Administration (FDA) for approval ... Aerosol for the long-term maintenance treatment of asthma ... SYMBICORT is currently approved,for the long-term maintenance treatment ...
Cached Medicine Technology:Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows 2Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows 3Heart Patients More Likely to Adopt Healthy Habits in 3-Year Program Led by Cardiac Rehabilitation Experts, Mayo Clinic Research Shows 4AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 2AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 3AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 4AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 5AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six 6
(Date:3/27/2015)... (PRWEB) March 27, 2015 While deep learning ... 2015 GPU technology conference (GTC) , the CEO of one ... and push the human lifespan well beyond the generally-agreed ceiling ... informatics company , is one of 12 companies recognized as ... other startups in the GTC Emerging Companies Summit ...
(Date:3/27/2015)... UK (PRWEB) March 27, 2015 DrugDev ... Melissa (Liss) Easy was named to the 2015 Philadelphia ... Under 40 list spotlights 40 dynamic, up-and-coming leaders less ... and community involvement. Winners are honored at an awards ... of the Philadelphia Business Journal. , Lyn Kremer, Publisher ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The report ... an essential source of information on and analysis of ... The population of the US in 2013 amounted to ... Rate (CAGR) of 0.8% from 2008. The country’s increasingly ... chronic diseases will help to boost the growth of ...
(Date:3/27/2015)... SMI (Silicon Microstructures, Inc.), a global ... the SM1120 MEMS based ultra-miniature pressure sensor designed especially ... at only 220um x 75um provides ample space for ... With industry leading in vivo drift performance of ... broad operating pressure range from 0 to 1,100 mmHg ...
(Date:3/27/2015)... When struck with the aftermath of a trucking ... begin. The latest eBook released by Dax Jones ... victims a clear and concise process for obtaining the ... injury claim is seen through to successful completion. , ... should be taken immediately following the trucking incident. From ...
Breaking Medicine News(10 mins):Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2
... new study shows that monitoring levels of exhaled nitric oxide ... improve the course of their disease. , The study ... is funded by the National Institute of Allergy and Infectious ... The Sept. 20 issue of The Lancet reports ...
... GetResearchSmart LLC serves as Guest Editor for a special issue of ... entitled Measuring Trust in Clinical Research. , ... St. ... of The Monitor, journal of the Association of Clinical Research Professionals ...
... ,do not board, list comes as a surprise to ... -- Thirty-three would-be air travelers with suspected or confirmed ... health "Do Not Board" list in the first year ... , Authorized under the Aviation and Transportation Security Act ...
... National Poll Shows Large Majority Supports Funding ... of the nation,s,largest veterans service organizations, representing ... Veterans, Affairs Committee Chairman Daniel,Akaka (D-Hawaii), House ... a group of bipartisan cosponsors for introducing,legislation ...
... a top concern for businesses of all sizes. Just when,employers ... these that complicate the enrollment:, -- Employees don,t ... of what their employer provides. -- Health ... -- A handful of employees who are located in remote ...
... WHITE PLAINS, N.Y., Sept. 18 Dee Snider,best known as ... Sister,is taking on a new lead role this year as ... is personal: two of his children were,born prematurely, and he,s ... Despite the wild-man image from his heavy metal days, Snider ...
Cached Medicine News:Health News:Monitoring exhaled nitric oxide does not help manage asthma 2Health News:Monitoring exhaled nitric oxide does not help manage asthma 3Health News:GetResearchSmart LLC Website Founder Honored as Guest Editor 2Health News:U.S. Barred 33 TB-Infected People From Flying Over Past Year 2Health News:U.S. Barred 33 TB-Infected People From Flying Over Past Year 3Health News:Historic Legislation to End Delays in Veterans Health Care Funding 2Health News:Historic Legislation to End Delays in Veterans Health Care Funding 3Health News:New Web-Based Enrollment System Gives Employers Flexibility and Control in Managing Benefits Enrollments 2Health News:New Web-Based Enrollment System Gives Employers Flexibility and Control in Managing Benefits Enrollments 3Health News:Dee Snider Joins March of Dimes Bikers for Babies(R) 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: